Ser146
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser146  -  DBNL (human)

Site Information
NysFHkEsGRFQDVG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15409242

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 )
Disease tissue studied:
gastric cancer ( 5 ) , gastric carcinoma ( 5 )
Relevant cell line - cell type - tissue:

References 

1

Liu N, Sun N, Gao X, Li Z (2014) Phosphosite mapping of HIP-55 protein in mammalian cells. Int J Mol Sci 15, 4903-14
24651461   Curated Info

2

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

3

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

4

Zhou J (2011) CST Curation Set: 12026; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info

5

Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info